By PR Newswire, September 25, 2013, 08:00:00 AM EDT
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, September 25, 2013 /PRNewswire/ --
Today, Investors' Reports announced new research reports highlighting Theravance, Inc. (NASDAQ:THRX), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Exelixis, Inc. (NASDAQ:EXEL), Verenium Corporation (NASDAQ:VRNM), and Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Theravance, Inc. Research Report
On September 20, 2013, Theravance, Inc. (Theravance), together with GlaxoSmithKline plc (GlaxoSmithKline), announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved RELVAR ELLIPTA for the treatment of bronchial asthma. The Company further informed that the MHLW has approved two doses of FF/VI - 100/25 mcg and 200/25 mcg. Darrell Baker, SVP and Head of GSK Global Respiratory Franchise said, "The approval of Relvar Ellipta in Japan means that, for the first time, people with asthma will be able to benefit from a once-daily ICS/LABA that delivers continuous 24-hour efficacy." The Company stated that under the terms of the 2002 LABA collaboration agreement, after MHLW approval of Relvar Ellipta in Japan, Theravance is obliged to make a milestone payment of $10 million to GSK. The Full Research Report on Theravance, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-23/THRX]
Arena Pharmaceuticals, Inc. Research Report
On September 18, 2013, Arena Pharmaceuticals, Inc. (Arena) announced that it will be presenting data from the BELVIQ (lorcaserin HCI) Phase 3 clinical trial program at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), being held from September 23 to September 27, 2013 in Barcelona, Spain. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-23/ARNA]
Exelixis, Inc. Research Report
On September 20, 2013, Exelixis, Inc. (Exelixis) announced that its President and CEO, Michael M. Morrissey, Ph.D., will represent the Company at BioCentury's NewsMakers in the Biotech Industry Conference, on September 27, 2013, at 1:30 p.m. EDT/10:30 a.m. PDT. The Company informed that during the presentation, Dr. Morrissey will review Exelixis' development plans and priorities for cabozantinib in 2013. Exelixix stated that he will also discuss the Company's corporate strategy and financial outlook, as well as provide a general business update. The Company informed that the live webcast of the presentation will be available at its website under investors & media section. The Full Research Report on Exelixis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-23/EXEL]
Verenium Corporation Research Report
On September 20, 2013, Verenium Corporation (Verenium) announced that it has entered into a definitive merger agreement with BASF Corporation (BASF). According to the Company, under the terms of the agreement, approved by the Board of Directors of both the companies, BASF will initiate a cash tender offer for all of the outstanding shares of Verenium's common stock and holders of outstanding shares of Verenium's common stock will receive $4.00 per share. Verenium stated that the tender offer is expected to close in Q4 2013, subject to standard closing conditions. The Full Research Report on Verenium Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-23/VRNM]
Enanta Pharmaceuticals, Inc. Research Report
On September 3, 2013, Enanta Pharmaceuticals, Inc. (Enanta) announced that the National Institute of Allergy and Infectious Disease (NIAID) - a division of the National Institutes of Health (NIH) will provide additional funding of $9.2 million to its current contract with Enanta to fund preclinical and early clinical development for Bicyclolides (a new class of bridged bicyclic antibiotics). Enanta stated that with the additional funding, the total funding amount goes upto c.$23.5 million. The Company informed that the funding could total c.$42.7 million if all project milestones under the multi-year contract awarded in 2011 are met, and NIAID exercises all its options to fund additional development under the contract. Enanta informed that IND enabling studies are currently ongoing and initiation of clinical trials is expected to commence in the H1 FY 2014 (period ending March, 31, 2014). The Full Research Report on Enanta Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-23/ENTA]
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investors' Reports